NKGen Biotech (NKGNW) Financials

$0.0002 0.00 (0.00%)
As of 11/6/2026
Annual Income Statements for NKGen Biotech

Annual Income Statements for NKGen Biotech

This table shows NKGen Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders
-27 -83 -44
Consolidated Net Income / (Loss)
-27 -83 -44
Net Income / (Loss) Continuing Operations
-27 -83 -44
Total Pre-Tax Income
-27 -83 -44
Total Operating Income
-24 -30 -27
Total Gross Profit
0.06 0.00 0.00
Total Revenue
0.08 0.00 0.00
Total Cost of Revenue
0.02 0.00 0.00
Total Operating Expenses
24 30 27
Selling, General & Admin Expense
7.66 14 16
Research & Development Expense
17 16 11
Total Other Income / (Expense), net
-2.22 -53 -17
Interest Expense
2.31 0.75 2.72
Interest & Investment Income
- - -4.65
Other Income / (Expense), net
0.08 -52 -9.89
Income Tax Expense
0.01 0.01 0.05
Basic Earnings per Share
($4.21) ($5.38) ($1.54)
Weighted Average Basic Shares Outstanding
6.36M 15.43M 28.83M
Diluted Earnings per Share
($4.21) ($5.38) ($1.54)
Weighted Average Diluted Shares Outstanding
6.36M 15.43M 28.83M

Quarterly Income Statements for NKGen Biotech

This table shows NKGen Biotech's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-33 -34 -5.38 -16 6.60 -29 15
Consolidated Net Income / (Loss)
-33 -34 -5.38 -16 6.60 -29 15
Net Income / (Loss) Continuing Operations
-33 -34 -5.38 -16 6.60 -29 15
Total Pre-Tax Income
-33 -34 -5.38 -16 6.60 -29 15
Total Operating Income
-6.90 -9.43 -7.62 -7.46 -6.79 -5.10 -4.67
Total Gross Profit
0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue
0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue
0.00 - 0.00 - - - 0.00
Total Cost of Revenue
0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses
6.90 9.43 7.62 7.46 6.79 5.10 4.67
Selling, General & Admin Expense
2.97 5.34 4.39 4.37 4.01 3.54 2.81
Research & Development Expense
3.93 4.09 3.24 3.09 2.78 1.56 1.86
Total Other Income / (Expense), net
-26 -24 2.24 -8.63 13 -24 20
Interest Expense
0.21 0.44 1.07 0.65 0.47 0.54 0.51
Interest & Investment Income
0.00 - 0.28 -5.22 1.00 - 0.00
Other Income / (Expense), net
-26 -24 3.03 -2.76 13 -23 21
Income Tax Expense
0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share
($2.48) ($1.68) ($0.25) ($0.67) $0.23 ($0.85) $0.33
Weighted Average Basic Shares Outstanding
13.40M 15.43M 21.94M 24.17M 29.13M 28.83M 45.96M
Diluted Earnings per Share
($2.48) ($1.68) ($0.25) ($0.67) $0.15 ($0.77) ($0.04)
Weighted Average Diluted Shares Outstanding
13.40M 15.43M 21.94M 24.17M 41.33M 28.83M 102.65M

Annual Cash Flow Statements for NKGen Biotech

This table details how cash moves in and out of NKGen Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents
-0.23 0.16 -0.04
Net Cash From Operating Activities
-23 -22 -21
Net Cash From Continuing Operating Activities
-23 -22 -21
Net Income / (Loss) Continuing Operations
-27 -83 -44
Consolidated Net Income / (Loss)
-27 -83 -44
Depreciation Expense
1.21 1.20 1.18
Amortization Expense
- 0.00 0.13
Non-Cash Adjustments To Reconcile Net Income
2.52 57 21
Changes in Operating Assets and Liabilities, net
0.47 2.61 1.54
Net Cash From Investing Activities
-0.16 -0.05 -0.01
Net Cash From Continuing Investing Activities
-0.16 -0.05 -0.01
Acquisitions
-0.06 -0.05 -0.05
Sale of Property, Plant & Equipment
- 0.00 0.04
Net Cash From Financing Activities
22 22 21
Net Cash From Continuing Financing Activities
22 22 21
Repayment of Debt
-0.68 -0.40 -2.96
Issuance of Debt
23 27 17
Issuance of Common Equity
0.00 12 0.10
Other Financing Activities, net
0.16 -16 6.43
Cash Interest Paid
0.04 0.24 0.95

Quarterly Cash Flow Statements for NKGen Biotech

This table details how cash moves in and out of NKGen Biotech's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents
7.56 -8.76 0.01 0.05 -0.09 -0.00 -0.21
Net Cash From Operating Activities
-4.57 -6.94 -4.03 -6.00 -3.90 -6.95 -2.80
Net Cash From Continuing Operating Activities
-4.57 -6.94 -4.03 -6.00 -3.90 -6.96 -2.80
Net Income / (Loss) Continuing Operations
-33 -34 -5.38 -16 6.60 -29 15
Consolidated Net Income / (Loss)
-33 -34 -5.38 -16 6.60 -29 15
Depreciation Expense
0.30 0.30 0.30 0.29 0.30 0.30 0.34
Amortization Expense
- - 0.03 0.03 0.04 0.04 0.04
Non-Cash Adjustments To Reconcile Net Income
27 25 -1.25 5.36 -12 25 -19
Changes in Operating Assets and Liabilities, net
1.08 1.51 2.28 4.41 1.60 -2.51 0.89
Net Cash From Investing Activities
- -0.02 0.04 -0.02 -0.02 -0.02 -0.05
Net Cash From Continuing Investing Activities
- -0.02 0.04 -0.02 -0.02 -0.02 -0.05
Acquisitions
- -0.02 0.00 -0.02 -0.02 -0.02 -0.05
Sale of Property, Plant & Equipment
- - 0.04 - - - 0.00
Net Cash From Financing Activities
12 -1.80 4.01 6.06 3.82 6.97 2.65
Net Cash From Continuing Financing Activities
12 -1.80 4.01 6.06 3.82 6.97 2.65
Repayment of Debt
0.03 -0.33 0.50 -1.73 -0.72 -0.50 -1.00
Issuance of Debt
13 0.06 1.47 8.29 2.74 4.78 1.89
Other Financing Activities, net
-13 -1.54 2.03 -1.37 2.83 2.69 1.76
Cash Interest Paid
- 0.24 0.12 0.10 0.18 0.55 0.13

Annual Balance Sheets for NKGen Biotech

This table presents NKGen Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets
174 16 16 16
Total Current Assets
2.54 0.35 1.93 2.46
Cash & Equivalents
1.72 0.12 0.03 0.11
Restricted Cash
- 0.00 0.25 0.13
Prepaid Expenses
0.81 0.20 1.65 2.22
Plant, Property, & Equipment, net
0.00 16 14 13
Total Noncurrent Assets
172 0.46 0.09 0.48
Intangible Assets
- 0.10 0.09 0.10
Other Noncurrent Operating Assets
172 0.36 0.00 0.38
Total Liabilities & Shareholders' Equity
174 16 16 16
Total Liabilities
13 15 75 86
Total Current Liabilities
1.89 15 39 58
Short-Term Debt
- 11 9.99 42
Accounts Payable
0.05 2.65 13 16
Other Current Liabilities
0.19 0.70 16 0.39
Total Noncurrent Liabilities
12 0.03 36 28
Long-Term Debt
- 0.00 9.93 11
Noncurrent Deferred & Payable Income Tax Liabilities
- 0.03 0.03 0.01
Other Noncurrent Operating Liabilities
12 0.00 26 17
Commitments & Contingencies
0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-11 1.56 -59 -70
Total Preferred & Common Equity
-11 1.56 -59 -70
Total Common Equity
-11 1.56 -59 -70
Common Stock
0.00 81 104 137
Retained Earnings
-11 -79 -162 -206

Quarterly Balance Sheets for NKGen Biotech

This table presents NKGen Biotech's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets
25 16 16 15 16
Total Current Assets
10 1.61 1.25 0.91 2.38
Cash & Equivalents
8.79 0.03 0.08 0.01 0.01
Restricted Cash
0.25 0.25 0.25 0.23 0.02
Prepaid Expenses
1.31 1.32 0.92 0.67 2.35
Plant, Property, & Equipment, net
15 14 14 14 13
Total Noncurrent Assets
0.18 0.57 0.54 0.51 0.44
Intangible Assets
0.09 0.09 0.09 0.09 0.10
Other Noncurrent Operating Assets
0.09 0.48 0.45 0.42 0.34
Total Liabilities & Shareholders' Equity
25 16 16 15 16
Total Liabilities
66 71 85 62 66
Total Current Liabilities
39 37 51 37 44
Short-Term Debt
5.23 11 17 20 27
Accounts Payable
13 15 15 17 17
Other Current Liabilities
21 11 19 0.81 0.39
Total Noncurrent Liabilities
27 34 34 25 22
Long-Term Debt
15 10 10 11 11
Noncurrent Deferred & Payable Income Tax Liabilities
0.03 0.03 0.03 0.03 0.01
Other Noncurrent Operating Liabilities
12 24 24 14 11
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-41 -55 -70 -47 -50
Total Preferred & Common Equity
-41 -55 -70 -47 -50
Total Common Equity
-41 -55 -70 -47 -50
Common Stock
88 112 114 130 141
Retained Earnings
-129 -168 -184 -177 -191

Annual Metrics And Ratios for NKGen Biotech

This table displays calculated financial ratios and metrics derived from NKGen Biotech's official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
DEI Shares Outstanding
21,451,875.00 21,888,976.00 35,362,376.00
DEI Adjusted Shares Outstanding
21,451,875.00 21,888,976.00 35,362,376.00
DEI Earnings Per Adjusted Shares Outstanding
-1.25 -3.79 -1.25
Growth Metrics
- - -
Revenue Growth
0.00% -100.00% 0.00%
EBITDA Growth
0.00% -251.34% 56.12%
EBIT Growth
0.00% -238.78% 55.16%
NOPAT Growth
0.00% -22.18% 9.35%
Net Income Growth
0.00% -210.06% 46.61%
EPS Growth
0.00% -27.79% 71.38%
Operating Cash Flow Growth
0.00% 2.70% 4.86%
Free Cash Flow Firm Growth
0.00% 0.00% -230.48%
Invested Capital Growth
0.00% -404.16% 55.46%
Revenue Q/Q Growth
0.00% -100.00% 0.00%
EBITDA Q/Q Growth
0.00% -17.71% 12.10%
EBIT Q/Q Growth
0.00% -17.39% 11.44%
NOPAT Q/Q Growth
0.00% 19.53% 13.85%
Net Income Q/Q Growth
0.00% -14.63% 8.65%
EPS Q/Q Growth
0.00% 22.48% 37.14%
Operating Cash Flow Q/Q Growth
0.00% -7.19% -0.07%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% -16.94%
Invested Capital Q/Q Growth
0.00% -31.32% -2.40%
Profitability Metrics
- - -
Gross Margin
76.62% 0.00% 0.00%
EBITDA Margin
-29,940.26% 0.00% 0.00%
Operating Margin
-31,618.18% 0.00% 0.00%
EBIT Margin
-31,511.69% 0.00% 0.00%
Profit (Net Income) Margin
-34,745.45% 0.00% 0.00%
Tax Burden Percent
100.03% 100.01% 100.12%
Interest Burden Percent
110.23% 100.91% 120.01%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-132.75% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-218.88% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
-1,578.96% 0.00% 0.00%
Return on Equity (ROE)
-1,711.71% 290.40% 68.87%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-25.47% 0.00% 0.00%
Return on Assets (ROA)
-28.09% 0.00% 0.00%
Return on Common Equity (ROCE)
98.43% 290.40% 68.87%
Return on Equity Simple (ROE_SIMPLE)
-1,711.71% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-17 -21 -19
NOPAT Margin
-22,132.73% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
86.14% 401.89% 70.42%
Return On Investment Capital (ROIC_SIMPLE)
- 53.70% 110.03%
Cost of Revenue to Revenue
23.38% 0.00% 0.00%
SG&A Expenses to Revenue
9,946.75% 0.00% 0.00%
R&D to Revenue
21,748.05% 0.00% 0.00%
Operating Expenses to Revenue
31,694.81% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-24 -82 -37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-23 -81 -36
Valuation Ratios
- - -
Price to Book Value (P/BV)
136.56 0.00 0.00
Price to Tangible Book Value (P/TBV)
145.60 0.00 0.00
Price to Revenue (P/Rev)
2,772.03 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
17.50 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
2,918.46 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 2.57 0.00
Leverage & Solvency
- - -
Debt to Equity
7.29 -0.34 -0.75
Long-Term Debt to Equity
0.00 -0.17 -0.16
Financial Leverage
7.21 -0.54 -0.56
Leverage Ratio
1.17 -0.57 -0.25
Compound Leverage Factor
1.29 -0.58 -0.31
Debt to Total Capital
87.94% -51.38% -307.48%
Short-Term Debt to Total Capital
87.94% -25.77% -244.29%
Long-Term Debt to Total Capital
0.00% -25.61% -63.19%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
12.06% 151.38% 407.48%
Debt to EBITDA
-0.49 -0.25 -1.48
Net Debt to EBITDA
-0.49 -0.24 -1.48
Long-Term Debt to EBITDA
0.00 -0.12 -0.31
Debt to NOPAT
-0.67 -0.96 -2.79
Net Debt to NOPAT
-0.66 -0.94 -2.78
Long-Term Debt to NOPAT
0.00 -0.48 -0.57
Altman Z-Score
-4.07 -32.48 -29.24
Noncontrolling Interest Sharing Ratio
105.75% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
0.02 0.05 0.04
Quick Ratio
0.01 0.00 0.00
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
0.00 31 -41
Operating Cash Flow to CapEx
-22,333.66% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 41.70 -14.88
Operating Cash Flow to Interest Expense
-9.78 -29.46 -7.67
Operating Cash Flow Less CapEx to Interest Expense
-9.83 -29.46 -7.65
Efficiency Ratios
- - -
Asset Turnover
0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00
Accounts Payable Turnover
0.01 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
27,413.60 0.00 0.00
Cash Conversion Cycle (CCC)
-27,413.60 0.00 0.00
Capital & Investment Metrics
- - -
Invested Capital
13 -39 -17
Invested Capital Turnover
0.01 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 -52 22
Enterprise Value (EV)
225 80 76
Market Capitalization
213 60 23
Book Value per Share
$0.07 ($2.68) ($1.98)
Tangible Book Value per Share
$0.07 ($2.69) ($1.98)
Total Capital
13 -39 -17
Total Debt
11 20 53
Total Long-Term Debt
0.00 9.93 11
Net Debt
11 20 53
Capital Expenditures (CapEx)
0.10 0.00 -0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-3.12 -28 -14
Debt-free Net Working Capital (DFNWC)
-3.00 -28 -14
Net Working Capital (NWC)
-14 -38 -56
Net Nonoperating Expense (NNE)
9.71 62 25
Net Nonoperating Obligations (NNO)
11 20 53
Total Depreciation and Amortization (D&A)
1.21 1.20 1.32
Debt-free, Cash-free Net Working Capital to Revenue
-4,046.75% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
-3,894.81% 0.00% 0.00%
Net Working Capital to Revenue
-18,689.61% 0.00% 0.00%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.00 ($5.38) ($1.54)
Adjusted Weighted Average Basic Shares Outstanding
0.00 15.43M 28.83M
Adjusted Diluted Earnings per Share
$0.00 ($5.38) ($1.54)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 15.43M 28.83M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-17 -21 -19
Normalized NOPAT Margin
-22,132.73% 0.00% 0.00%
Pre Tax Income Margin
-34,736.36% 0.00% 0.00%
Debt Service Ratios
- - -
EBIT to Interest Expense
-10.52 -110.34 -13.53
NOPAT to Interest Expense
-7.39 -27.95 -6.93
EBIT Less CapEx to Interest Expense
-10.57 -110.34 -13.52
NOPAT Less CapEx to Interest Expense
-7.43 -27.95 -6.92
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for NKGen Biotech

This table displays calculated financial ratios and metrics derived from NKGen Biotech's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
DEI Shares Outstanding
10,373,875.00 21,888,976.00 21,888,976.00 24,887,799.00 35,362,376.00 35,362,376.00 44,947,588.00
DEI Adjusted Shares Outstanding
10,373,875.00 21,888,976.00 21,888,976.00 24,887,799.00 35,362,376.00 35,362,376.00 44,947,588.00
DEI Earnings Per Adjusted Shares Outstanding
-3.20 -1.54 -0.25 -0.65 0.19 -0.83 0.34
Growth Metrics
- - - - - - -
Revenue Growth
-100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-439.31% -58.93% 46.52% -32.12% 119.60% 14.59% 480.28%
EBIT Growth
-444.26% -58.04% 44.55% -31.23% 118.42% 14.36% 445.06%
NOPAT Growth
-15.20% 43.35% -12.11% -12.80% -40.48% 45.94% 12.53%
Net Income Growth
-395.70% -45.98% 35.33% -104.97% 119.89% 12.47% 385.21%
EPS Growth
-125.45% 48.15% 60.32% -13.56% 106.05% 54.17% 84.00%
Operating Cash Flow Growth
72.55% -26.95% 17.91% -8.48% 14.68% -0.20% 30.59%
Free Cash Flow Firm Growth
1,760.16% 0.00% 1,662.08% -14.09% -110.15% -155.71% -113.14%
Invested Capital Growth
-117.75% -404.16% -120.00% -177.61% 42.89% 55.46% 62.98%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-336.24% -0.60% 87.01% -148.13% 164.72% -538.34% 157.85%
EBIT Q/Q Growth
-323.35% -0.59% 86.14% -136.93% 159.41% -567.76% 155.85%
NOPAT Q/Q Growth
-4.42% -36.67% 19.22% 2.15% -30.04% 47.41% -30.70%
Net Income Q/Q Growth
-322.69% -1.29% 83.99% -198.92% 141.01% -545.80% 152.19%
EPS Q/Q Growth
-320.34% 32.26% 85.12% -168.00% 122.39% -613.33% 94.81%
Operating Cash Flow Q/Q Growth
17.45% -52.00% 41.86% -48.71% 35.07% -78.51% 59.73%
Free Cash Flow Firm Q/Q Growth
80.09% -76.47% 336.56% -53.56% -121.28% -29.10% -2.98%
Invested Capital Q/Q Growth
-154.43% -31.32% 13.33% -25.29% 59.94% -2.40% 27.96%
Profitability Metrics
- - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.02% 100.00% 100.00% 100.00% 100.18% 100.00%
Interest Burden Percent
100.64% 101.32% 117.10% 157.43% 108.68% 103.39% 96.79%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% 290.40% -139.97% 1,141.70% 110.57% 68.87% 44.70%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
0.00% 290.40% 73.89% 5,779.18% 110.57% 68.87% 44.70%
Return on Equity Simple (ROE_SIMPLE)
178.08% 0.00% 0.00% 126.59% 103.04% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-4.83 -6.60 -5.33 -5.22 -6.79 -3.57 -4.67
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
557.20% 174.66% 0.45% 78.49% -65.35% 71.63% -67.83%
Return On Investment Capital (ROIC_SIMPLE)
23.34% 17.03% 15.90% - 40.54% 20.81% 37.33%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-33 -33 -4.60 -10 6.07 -28 16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-33 -33 -4.27 -9.89 6.40 -28 16
Valuation Ratios
- - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
919.63 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
1,066.95 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 2.57 0.34 0.79 0.00 0.00 0.00
Leverage & Solvency
- - - - - - -
Debt to Equity
-0.49 -0.34 -0.39 -0.40 -0.64 -0.75 -0.75
Long-Term Debt to Equity
-0.36 -0.17 -0.18 -0.15 -0.23 -0.16 -0.22
Financial Leverage
0.08 -0.54 0.18 -1.79 -0.47 -0.56 -0.56
Leverage Ratio
1.56 -0.57 1.68 -5.13 -0.46 -0.25 -0.31
Compound Leverage Factor
1.57 -0.58 1.97 -8.07 -0.50 -0.26 -0.30
Debt to Total Capital
-96.32% -51.38% -64.06% -65.72% -180.96% -307.48% -302.69%
Short-Term Debt to Total Capital
-25.27% -25.77% -33.82% -41.06% -117.64% -244.29% -214.07%
Long-Term Debt to Total Capital
-71.05% -25.61% -30.24% -24.65% -63.32% -63.19% -88.62%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
196.32% 151.38% 164.06% 165.72% 280.96% 407.48% 402.69%
Debt to EBITDA
-0.29 -0.25 -0.28 -0.35 -0.75 -1.48 -2.52
Net Debt to EBITDA
-0.16 -0.24 -0.27 -0.34 -0.74 -1.48 -2.51
Long-Term Debt to EBITDA
-0.21 -0.12 -0.13 -0.13 -0.26 -0.31 -0.74
Debt to NOPAT
-0.77 -0.96 -1.00 -1.26 -1.38 -2.79 -2.25
Net Debt to NOPAT
-0.42 -0.94 -0.99 -1.24 -1.37 -2.78 -2.25
Long-Term Debt to NOPAT
-0.57 -0.48 -0.47 -0.47 -0.48 -0.57 -0.66
Altman Z-Score
-12.19 -22.66 -17.59 -22.21 -17.96 -27.52 -16.65
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 152.79% -406.19% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - -
Current Ratio
0.27 0.05 0.04 0.02 0.02 0.04 0.05
Quick Ratio
0.23 0.00 0.00 0.00 0.00 0.00 0.00
Cash Flow Metrics
- - - - - - -
Free Cash Flow to Firm (FCFF)
192 45 198 92 -20 -25 -26
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
912.17 103.38 184.93 141.90 -41.40 -47.07 -51.04
Operating Cash Flow to Interest Expense
-21.64 -15.84 -3.77 -9.27 -8.25 -12.97 -5.50
Operating Cash Flow Less CapEx to Interest Expense
-21.64 -15.84 -3.74 -9.27 -8.25 -12.97 -5.50
Efficiency Ratios
- - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
133,954.25 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
-133,954.25 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - -
Invested Capital
-30 -39 -34 -42 -17 -17 -13
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-197 -52 -203 -97 13 22 21
Enterprise Value (EV)
79 80 63 59 43 76 46
Market Capitalization
68 60 41 32 13 23 8.09
Book Value per Share
($3.92) ($2.68) ($2.52) ($2.80) ($1.33) ($1.98) ($1.12)
Tangible Book Value per Share
($3.93) ($2.69) ($2.52) ($2.81) ($1.33) ($1.98) ($1.12)
Total Capital
-21 -39 -34 -42 -17 -17 -12
Total Debt
20 20 21 28 30 53 38
Total Long-Term Debt
15 9.93 10 10 11 11 11
Net Debt
11 20 21 27 30 53 38
Capital Expenditures (CapEx)
0.00 0.00 -0.04 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-32 -28 -25 -33 -17 -14 -15
Debt-free Net Working Capital (DFNWC)
-23 -28 -25 -33 -17 -14 -15
Net Working Capital (NWC)
-28 -38 -36 -50 -36 -56 -42
Net Nonoperating Expense (NNE)
28 27 0.05 11 -13 26 -20
Net Nonoperating Obligations (NNO)
11 20 21 27 30 53 38
Total Depreciation and Amortization (D&A)
0.30 0.30 0.33 0.33 0.33 0.33 0.38
Debt-free, Cash-free Net Working Capital to Revenue
-43,654.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
-31,443.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
-38,512.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - -
Adjusted Basic Earnings per Share
($2.48) ($1.68) ($0.25) ($0.67) $0.23 ($0.85) $0.33
Adjusted Weighted Average Basic Shares Outstanding
13.40M 15.43M 21.94M 24.17M 29.13M 28.83M 45.96M
Adjusted Diluted Earnings per Share
($2.48) ($1.68) ($0.25) ($0.67) $0.15 ($0.77) ($0.04)
Adjusted Weighted Average Diluted Shares Outstanding
13.40M 15.43M 21.94M 24.17M 41.33M 28.83M 102.65M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
21.89M 0.00 24.89M 35.36M 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-4.83 -6.60 -5.33 -5.22 -4.75 -3.57 -3.27
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - -
EBIT to Interest Expense
-156.24 -75.71 -4.30 -15.79 12.86 -52.98 31.16
NOPAT to Interest Expense
-22.90 -15.08 -4.99 -8.07 -14.38 -6.66 -9.17
EBIT Less CapEx to Interest Expense
-156.24 -75.71 -4.27 -15.79 12.86 -52.98 31.16
NOPAT Less CapEx to Interest Expense
-22.90 -15.08 -4.96 -8.07 -14.38 -6.66 -9.17
Payout Ratios
- - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

NKGen Biotech’s financial statements show a development-stage company with no reported revenue in any of the periods provided. The company continues to fund research and general operations primarily through debt, equity-related financing and other financing activities rather than through operating cash flow.

There are some signs of improving cost control. Quarterly operating expenses declined from $9.4 million in Q4 2023 to $4.7 million in Q1 2025. Operating cash outflow also improved to $2.8 million in Q1 2025, compared with $7.0 million in Q4 2024. However, the company’s reported Q1 profit was largely driven by $20.5 million of other income, not by revenue or core operations, and should not be viewed as evidence of sustainable profitability.

  • Operating expenses are trending lower: Total operating expenses fell from $9.4 million in Q4 2023 to $5.1 million in Q4 2024 and $4.7 million in Q1 2025. Both SG&A and research and development expenses declined sequentially in Q1 2025.
  • Operating cash burn improved in Q1 2025: Net cash used in operating activities was $2.8 million, better than $7.0 million in Q4 2024 and $6.0 million in Q2 2024. Continued improvement would extend the company’s financial runway.
  • Financing activity has continued to provide liquidity: NKGen generated $2.6 million from financing activities in Q1 2025, following $7.0 million in Q4 2024 and $3.8 million in Q3 2024.
  • Total liabilities have declined from 2024 levels: Liabilities fell from $85.4 million in Q2 2024 to $66.2 million in Q1 2025. Negative equity also improved from negative $69.7 million to negative $50.3 million over the same period, although the balance sheet remains highly leveraged.
  • Q1 2025 reported net income of $15.4 million: The result compares with losses of $29.4 million in Q4 2024 and $16.1 million in Q2 2024, but the improvement was primarily caused by $20.5 million of other income. The company still generated an operating loss of $4.7 million and reported no revenue.
  • Cash flow contains substantial noncash adjustments: Q1 2025 included a negative $19.4 million noncash adjustment to reconcile net income to operating cash flow. This highlights the difference between reported earnings and the company’s actual cash position.
  • NKGen has not yet generated operating revenue: Revenue was reported as zero in Q1, Q2 and Q3 2024, Q4 2024, and Q1 2025. Without a commercial revenue base, the company remains dependent on external financing.
  • Liquidity is extremely limited: Q1 2025 cash and equivalents were only $6,000, down from $8.8 million in Q3 2023 and $34,000 in Q1 2024. Including restricted cash, the company had just $29,000 of cash-related funds, while prepaid expenses represented most of its $2.4 million of current assets.
  • Current liabilities substantially exceed current assets: Q1 2025 current liabilities were $43.9 million versus current assets of $2.4 million. Short-term debt was $26.8 million and accounts payable was $16.7 million, indicating significant near-term obligations.
  • Shareholder dilution and negative equity remain major risks: Weighted-average basic shares increased from 13.4 million in Q3 2023 to 46.0 million in Q1 2025. Retained earnings were negative $191.1 million, producing total common equity of negative $50.3 million and increasing the likelihood of additional capital raises.
11/18/26 12:18 AM ETAI Generated. May Contain Errors.

NKGen Biotech Financials - Frequently Asked Questions

According to the most recent income statement we have on file, NKGen Biotech's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

NKGen Biotech's net income appears to be on a downward trend, with a most recent value of -$44.29 million in 2024, falling from -$26.75 million in 2022. The previous period was -$82.95 million in 2023.

NKGen Biotech's total operating income in 2024 was -$26.97 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $26.97 million

Over the last 2 years, NKGen Biotech's total revenue changed from $77 thousand in 2022 to $0.00 in 2024, a change of -100.0%.

In the past 6 quarters, NKGen Biotech's cash and equivalents has ranged from $6 thousand in Q1 2025 to $8.79 million in Q3 2023, and is currently $6 thousand as of their latest financial filing in Q1 2025.

NKGen Biotech had total debt of $52.75 million at the end of 2024, a 164.8% increase from 2023, and a 363.1% increase since 2022.

Over the last 2 years, NKGen Biotech's book value per share changed from 0.07 in 2022 to -1.98 in 2024.



Financial statements for NASDAQ:NKGNW last updated on 7/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners